TY  - JOUR
AU  - Dimić-Janjić, Sanja
AU  - Hoda, Mir Alireza
AU  - Milenković, Branislava
AU  - Kotur-Stevuljević, Jelena
AU  - Stjepanović, Mihailo
AU  - Gompelmann, Daniela
AU  - Janković, Jelena
AU  - Miljković, Milica
AU  - Milin-Lazović, Jelena
AU  - Đurđević, Nataša
AU  - Marić, Dragana
AU  - Milivojević, Ivan
AU  - Popević, Spasoje
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4612
AB  - Background: Inflammation, oxidative stress and an imbalance between proteases and protease inhibitors are recognized pathophysiological features of chronic obstructive pulmonary disease (COPD). The aim of this study was to evaluate serum levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with COPD and to assess their relationship with lung function, symptom severity scores and recent acute exacerbations. Methods: In this observational cohort study, serum levels of MMP-9 and TIMP-1 and the MMP-9/TIMP-1 ratio in the peripheral blood of COPD patients with stable disease and healthy controls were determined, and their association with lung function (postbronchodilator spirometry, body plethysmography, single breath diffusion capacity for carbon monoxide), symptom severity scores (mMRC and CAT) and exacerbation history were assessed. Results: COPD patients (n = 98) had significantly higher levels of serum MMP-9 and TIMP-1 and a higher MMP-9/TIMP-1 ratio than healthy controls (n = 47) (p ≤ 0.001). The areas under the receiver operating characteristic curve for MMP-9, TIMP-1 and the MMP-9/TIMP-1 ratio for COPD diagnosis were 0.974, 0.961 and 0.910, respectively (all p < 0.05). MMP-9 and the MMP-9/TIMP-1 ratio were both negatively correlated with FVC, FEV1, FEV1/FVC, VC, and IC (all p < 0.05). For MMP-9, a positive correlation was found with RV/TLC% (p = 0.005), and a positive correlation was found for the MMP-9/TIMP-1 ratio with RV% and RV/TLC% (p = 0.013 and 0.002, respectively). Patients with COPD GOLD 3 and 4 presented greater MMP-9 levels and a greater MMP-9/TIMP-1 ratio compared to GOLD 1 and 2 patients (p ≤ 0.001). No correlation between diffusion capacity for carbon monoxide and number of acute exacerbations in the previous year was found. Conclusions: COPD patients have elevated serum levels of MMP-9 and TIMP-1 and MMP-9/TIMP-1 ratio. COPD patients have an imbalance between MMP-9 and TIMP-1 in favor of a pro-proteolytic environment, which overall indicates the importance of the MMP-9/TIMP-1 ratio as a potential biomarker for COPD diagnosis and severity.
PB  - BioMed Central Ltd
T2  - European Journal of Medical Research
T1  - The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity
VL  - 28
IS  - 1
DO  - 10.1186/s40001-023-01094-7
ER  - 

@article{
author = "Dimić-Janjić, Sanja and Hoda, Mir Alireza and Milenković, Branislava and Kotur-Stevuljević, Jelena and Stjepanović, Mihailo and Gompelmann, Daniela and Janković, Jelena and Miljković, Milica and Milin-Lazović, Jelena and Đurđević, Nataša and Marić, Dragana and Milivojević, Ivan and Popević, Spasoje",
year = "2023",
abstract = "Background: Inflammation, oxidative stress and an imbalance between proteases and protease inhibitors are recognized pathophysiological features of chronic obstructive pulmonary disease (COPD). The aim of this study was to evaluate serum levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with COPD and to assess their relationship with lung function, symptom severity scores and recent acute exacerbations. Methods: In this observational cohort study, serum levels of MMP-9 and TIMP-1 and the MMP-9/TIMP-1 ratio in the peripheral blood of COPD patients with stable disease and healthy controls were determined, and their association with lung function (postbronchodilator spirometry, body plethysmography, single breath diffusion capacity for carbon monoxide), symptom severity scores (mMRC and CAT) and exacerbation history were assessed. Results: COPD patients (n = 98) had significantly higher levels of serum MMP-9 and TIMP-1 and a higher MMP-9/TIMP-1 ratio than healthy controls (n = 47) (p ≤ 0.001). The areas under the receiver operating characteristic curve for MMP-9, TIMP-1 and the MMP-9/TIMP-1 ratio for COPD diagnosis were 0.974, 0.961 and 0.910, respectively (all p < 0.05). MMP-9 and the MMP-9/TIMP-1 ratio were both negatively correlated with FVC, FEV1, FEV1/FVC, VC, and IC (all p < 0.05). For MMP-9, a positive correlation was found with RV/TLC% (p = 0.005), and a positive correlation was found for the MMP-9/TIMP-1 ratio with RV% and RV/TLC% (p = 0.013 and 0.002, respectively). Patients with COPD GOLD 3 and 4 presented greater MMP-9 levels and a greater MMP-9/TIMP-1 ratio compared to GOLD 1 and 2 patients (p ≤ 0.001). No correlation between diffusion capacity for carbon monoxide and number of acute exacerbations in the previous year was found. Conclusions: COPD patients have elevated serum levels of MMP-9 and TIMP-1 and MMP-9/TIMP-1 ratio. COPD patients have an imbalance between MMP-9 and TIMP-1 in favor of a pro-proteolytic environment, which overall indicates the importance of the MMP-9/TIMP-1 ratio as a potential biomarker for COPD diagnosis and severity.",
publisher = "BioMed Central Ltd",
journal = "European Journal of Medical Research",
title = "The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity",
volume = "28",
number = "1",
doi = "10.1186/s40001-023-01094-7"
}

Dimić-Janjić, S., Hoda, M. A., Milenković, B., Kotur-Stevuljević, J., Stjepanović, M., Gompelmann, D., Janković, J., Miljković, M., Milin-Lazović, J., Đurđević, N., Marić, D., Milivojević, I.,& Popević, S.. (2023). The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity. in European Journal of Medical Research
BioMed Central Ltd., 28(1).
https://doi.org/10.1186/s40001-023-01094-7

Dimić-Janjić S, Hoda MA, Milenković B, Kotur-Stevuljević J, Stjepanović M, Gompelmann D, Janković J, Miljković M, Milin-Lazović J, Đurđević N, Marić D, Milivojević I, Popević S. The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity. in European Journal of Medical Research. 2023;28(1).
doi:10.1186/s40001-023-01094-7 .

Dimić-Janjić, Sanja, Hoda, Mir Alireza, Milenković, Branislava, Kotur-Stevuljević, Jelena, Stjepanović, Mihailo, Gompelmann, Daniela, Janković, Jelena, Miljković, Milica, Milin-Lazović, Jelena, Đurđević, Nataša, Marić, Dragana, Milivojević, Ivan, Popević, Spasoje, "The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity" in European Journal of Medical Research, 28, no. 1 (2023),
https://doi.org/10.1186/s40001-023-01094-7 . .

TY  - JOUR
AU  - Jovanović, Dragana
AU  - Roksandić-Milenković, Marina
AU  - Kotur-Stevuljević, Jelena
AU  - Ceriman, Vesna
AU  - Vukanić, Ivana
AU  - Samardžić, Natalija
AU  - Popević, Spasoje
AU  - Ilić, Branislav
AU  - Gajić, Milija
AU  - Simon, Marioara
AU  - Simon, Ioan
AU  - Spasojević-Kalimanovska, Vesna
AU  - Belić, Milica
AU  - Mirkov, Damjan
AU  - Šumarac, Zorica
AU  - Milenković, Vladislav
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3341
AB  - Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer
VL  - 38
IS  - 3
SP  - 332
EP  - 341
DO  - 10.2478/jomb-2018-0036
ER  - 

@article{
author = "Jovanović, Dragana and Roksandić-Milenković, Marina and Kotur-Stevuljević, Jelena and Ceriman, Vesna and Vukanić, Ivana and Samardžić, Natalija and Popević, Spasoje and Ilić, Branislav and Gajić, Milija and Simon, Marioara and Simon, Ioan and Spasojević-Kalimanovska, Vesna and Belić, Milica and Mirkov, Damjan and Šumarac, Zorica and Milenković, Vladislav",
year = "2019",
abstract = "Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer",
volume = "38",
number = "3",
pages = "332-341",
doi = "10.2478/jomb-2018-0036"
}

Jovanović, D., Roksandić-Milenković, M., Kotur-Stevuljević, J., Ceriman, V., Vukanić, I., Samardžić, N., Popević, S., Ilić, B., Gajić, M., Simon, M., Simon, I., Spasojević-Kalimanovska, V., Belić, M., Mirkov, D., Šumarac, Z.,& Milenković, V.. (2019). Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(3), 332-341.
https://doi.org/10.2478/jomb-2018-0036

Jovanović D, Roksandić-Milenković M, Kotur-Stevuljević J, Ceriman V, Vukanić I, Samardžić N, Popević S, Ilić B, Gajić M, Simon M, Simon I, Spasojević-Kalimanovska V, Belić M, Mirkov D, Šumarac Z, Milenković V. Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. in Journal of Medical Biochemistry. 2019;38(3):332-341.
doi:10.2478/jomb-2018-0036 .

Jovanović, Dragana, Roksandić-Milenković, Marina, Kotur-Stevuljević, Jelena, Ceriman, Vesna, Vukanić, Ivana, Samardžić, Natalija, Popević, Spasoje, Ilić, Branislav, Gajić, Milija, Simon, Marioara, Simon, Ioan, Spasojević-Kalimanovska, Vesna, Belić, Milica, Mirkov, Damjan, Šumarac, Zorica, Milenković, Vladislav, "Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer" in Journal of Medical Biochemistry, 38, no. 3 (2019):332-341,
https://doi.org/10.2478/jomb-2018-0036 . .

TY  - CONF
AU  - Jovanović, Dragana M.
AU  - Kotur-Stevuljević, Jelena
AU  - Marković, Jelena
AU  - Loncarević, Olivera
AU  - Simon, Marioara
AU  - Milenković, Marina
AU  - Vukanić, Ivana
AU  - Kontić, Milica
AU  - Samardžić, Natalija
AU  - Ceriman, Vesna
AU  - Popević, Spasoje
AU  - Glumac, Sofija
AU  - Skodrić-Trifunović, Vesna
AU  - Radojević-Skodrić, Sanja
AU  - Ilić, Branislav
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3133
PB  - European Respiratory Soc Journals Ltd, Sheffield
C3  - European Respiratory Journal
T1  - PD-L1 expression on alveolar macrophages and in plasma of IPF patients - original research
VL  - 52
DO  - 10.1183/13993003.congress-2018.PA4232
ER  - 

@conference{
author = "Jovanović, Dragana M. and Kotur-Stevuljević, Jelena and Marković, Jelena and Loncarević, Olivera and Simon, Marioara and Milenković, Marina and Vukanić, Ivana and Kontić, Milica and Samardžić, Natalija and Ceriman, Vesna and Popević, Spasoje and Glumac, Sofija and Skodrić-Trifunović, Vesna and Radojević-Skodrić, Sanja and Ilić, Branislav",
year = "2018",
publisher = "European Respiratory Soc Journals Ltd, Sheffield",
journal = "European Respiratory Journal",
title = "PD-L1 expression on alveolar macrophages and in plasma of IPF patients - original research",
volume = "52",
doi = "10.1183/13993003.congress-2018.PA4232"
}

Jovanović, D. M., Kotur-Stevuljević, J., Marković, J., Loncarević, O., Simon, M., Milenković, M., Vukanić, I., Kontić, M., Samardžić, N., Ceriman, V., Popević, S., Glumac, S., Skodrić-Trifunović, V., Radojević-Skodrić, S.,& Ilić, B.. (2018). PD-L1 expression on alveolar macrophages and in plasma of IPF patients - original research. in European Respiratory Journal
European Respiratory Soc Journals Ltd, Sheffield., 52.
https://doi.org/10.1183/13993003.congress-2018.PA4232

Jovanović DM, Kotur-Stevuljević J, Marković J, Loncarević O, Simon M, Milenković M, Vukanić I, Kontić M, Samardžić N, Ceriman V, Popević S, Glumac S, Skodrić-Trifunović V, Radojević-Skodrić S, Ilić B. PD-L1 expression on alveolar macrophages and in plasma of IPF patients - original research. in European Respiratory Journal. 2018;52.
doi:10.1183/13993003.congress-2018.PA4232 .

Jovanović, Dragana M., Kotur-Stevuljević, Jelena, Marković, Jelena, Loncarević, Olivera, Simon, Marioara, Milenković, Marina, Vukanić, Ivana, Kontić, Milica, Samardžić, Natalija, Ceriman, Vesna, Popević, Spasoje, Glumac, Sofija, Skodrić-Trifunović, Vesna, Radojević-Skodrić, Sanja, Ilić, Branislav, "PD-L1 expression on alveolar macrophages and in plasma of IPF patients - original research" in European Respiratory Journal, 52 (2018),
https://doi.org/10.1183/13993003.congress-2018.PA4232 . .

TY  - CONF
AU  - Jovanović, Dragana M.
AU  - Kotur-Stevuljević, Jelena
AU  - Roksandić-Milenković, Marina
AU  - Simon, Marioara
AU  - Ceriman, Vesna
AU  - Popević, Spasoje
AU  - Vukanić, Ivana
AU  - Samardžić, Natalija
AU  - Kontić, Milica
AU  - Ilić, Branislav
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3119
PB  - European Respiratory Soc Journals Ltd, Sheffield
C3  - European Respiratory Journal
T1  - Soluble sPD-L1 plasma concentrations in a series of 95 lung cancer patients
VL  - 52
DO  - 10.1183/13993003.congress-2018.PA2218
ER  - 

@conference{
author = "Jovanović, Dragana M. and Kotur-Stevuljević, Jelena and Roksandić-Milenković, Marina and Simon, Marioara and Ceriman, Vesna and Popević, Spasoje and Vukanić, Ivana and Samardžić, Natalija and Kontić, Milica and Ilić, Branislav",
year = "2018",
publisher = "European Respiratory Soc Journals Ltd, Sheffield",
journal = "European Respiratory Journal",
title = "Soluble sPD-L1 plasma concentrations in a series of 95 lung cancer patients",
volume = "52",
doi = "10.1183/13993003.congress-2018.PA2218"
}

Jovanović, D. M., Kotur-Stevuljević, J., Roksandić-Milenković, M., Simon, M., Ceriman, V., Popević, S., Vukanić, I., Samardžić, N., Kontić, M.,& Ilić, B.. (2018). Soluble sPD-L1 plasma concentrations in a series of 95 lung cancer patients. in European Respiratory Journal
European Respiratory Soc Journals Ltd, Sheffield., 52.
https://doi.org/10.1183/13993003.congress-2018.PA2218

Jovanović DM, Kotur-Stevuljević J, Roksandić-Milenković M, Simon M, Ceriman V, Popević S, Vukanić I, Samardžić N, Kontić M, Ilić B. Soluble sPD-L1 plasma concentrations in a series of 95 lung cancer patients. in European Respiratory Journal. 2018;52.
doi:10.1183/13993003.congress-2018.PA2218 .

Jovanović, Dragana M., Kotur-Stevuljević, Jelena, Roksandić-Milenković, Marina, Simon, Marioara, Ceriman, Vesna, Popević, Spasoje, Vukanić, Ivana, Samardžić, Natalija, Kontić, Milica, Ilić, Branislav, "Soluble sPD-L1 plasma concentrations in a series of 95 lung cancer patients" in European Respiratory Journal, 52 (2018),
https://doi.org/10.1183/13993003.congress-2018.PA2218 . .

TY  - JOUR
AU  - Popević, Spasoje
AU  - Šumarac, Zorica
AU  - Jovanović, Dragana
AU  - Babić, Dragan
AU  - Stjepanović, Mihailo
AU  - Jovičić, Snežana
AU  - Sobić-Saranović, Dragana
AU  - Filipović, Snežana
AU  - Gvozdenović, Branko
AU  - Omcikus, Maja
AU  - Milovanović, Andela
AU  - Videnović-Ivanov, Jelica
AU  - Radović, Ana
AU  - Zugić, Vladimir
AU  - Vučinić-Mihailović, Violeta
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2749
AB  - Background: Until now, a proper biomarker(s) to evaluate sarcoidosis activity has not been recognized. The aims of this study were to evaluate the sensitivity and specificity of the two biomarkers of sarcoidosis activity already in use (serum angiotensin converting enzyme - ACE and serum chitotriosidase) in a population of 430 sarcoidosis patients. The activities of these markers were also analyzed in a group of 264 healthy controls. Methods: Four hundred and thirty biopsy positive sarcoidosis patients were divided into groups with active and inactive disease, and groups with acute or chronic disease. In a subgroup of 55 sarcoidosis patients, activity was also assessed by F-18 fluorodeoxyglucose positron emission tomography (F-18-FDG-PET) scanning. Both serum chitotriosidase and ACE levels showed non-normal distribution, so nonparametric tests were used in statistical analysis. Results: Serum chitotriosidase activities were almost 6 times higher in patients with active sarcoidosis than in healthy controls and inactive disease. A serum chitotriosidase value of 100 nmol/mL/h had the sensitivity of 82.5% and specificity of 70.0%. A serum ACE activity cutoff value of 32.0 U/L had the sensitivity of 66.0% and the specificity of 54%. A statistically significant correlation was obtained between the focal granulomatous activity detected on F-18-FDG PET/CT and serum chitotriosidase levels, but no such correlation was found with ACE. The levels of serum chitotriosidase activity significantly correlated with the disease duration (P lt 0.0001). Also, serum chitotriosidase significantly correlated with clinical outcome status (COS) categories (rho=0.272, P=0.001). Conclusions: Serum chitotriosidase proved to be a reliable biomarker of sarcoidosis activity and disease chronicity.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study
VL  - 35
IS  - 4
SP  - 390
EP  - 400
DO  - 10.1515/jomb-2016-0017
ER  - 

@article{
author = "Popević, Spasoje and Šumarac, Zorica and Jovanović, Dragana and Babić, Dragan and Stjepanović, Mihailo and Jovičić, Snežana and Sobić-Saranović, Dragana and Filipović, Snežana and Gvozdenović, Branko and Omcikus, Maja and Milovanović, Andela and Videnović-Ivanov, Jelica and Radović, Ana and Zugić, Vladimir and Vučinić-Mihailović, Violeta",
year = "2016",
abstract = "Background: Until now, a proper biomarker(s) to evaluate sarcoidosis activity has not been recognized. The aims of this study were to evaluate the sensitivity and specificity of the two biomarkers of sarcoidosis activity already in use (serum angiotensin converting enzyme - ACE and serum chitotriosidase) in a population of 430 sarcoidosis patients. The activities of these markers were also analyzed in a group of 264 healthy controls. Methods: Four hundred and thirty biopsy positive sarcoidosis patients were divided into groups with active and inactive disease, and groups with acute or chronic disease. In a subgroup of 55 sarcoidosis patients, activity was also assessed by F-18 fluorodeoxyglucose positron emission tomography (F-18-FDG-PET) scanning. Both serum chitotriosidase and ACE levels showed non-normal distribution, so nonparametric tests were used in statistical analysis. Results: Serum chitotriosidase activities were almost 6 times higher in patients with active sarcoidosis than in healthy controls and inactive disease. A serum chitotriosidase value of 100 nmol/mL/h had the sensitivity of 82.5% and specificity of 70.0%. A serum ACE activity cutoff value of 32.0 U/L had the sensitivity of 66.0% and the specificity of 54%. A statistically significant correlation was obtained between the focal granulomatous activity detected on F-18-FDG PET/CT and serum chitotriosidase levels, but no such correlation was found with ACE. The levels of serum chitotriosidase activity significantly correlated with the disease duration (P lt 0.0001). Also, serum chitotriosidase significantly correlated with clinical outcome status (COS) categories (rho=0.272, P=0.001). Conclusions: Serum chitotriosidase proved to be a reliable biomarker of sarcoidosis activity and disease chronicity.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study",
volume = "35",
number = "4",
pages = "390-400",
doi = "10.1515/jomb-2016-0017"
}

Popević, S., Šumarac, Z., Jovanović, D., Babić, D., Stjepanović, M., Jovičić, S., Sobić-Saranović, D., Filipović, S., Gvozdenović, B., Omcikus, M., Milovanović, A., Videnović-Ivanov, J., Radović, A., Zugić, V.,& Vučinić-Mihailović, V.. (2016). Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 35(4), 390-400.
https://doi.org/10.1515/jomb-2016-0017

Popević S, Šumarac Z, Jovanović D, Babić D, Stjepanović M, Jovičić S, Sobić-Saranović D, Filipović S, Gvozdenović B, Omcikus M, Milovanović A, Videnović-Ivanov J, Radović A, Zugić V, Vučinić-Mihailović V. Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study. in Journal of Medical Biochemistry. 2016;35(4):390-400.
doi:10.1515/jomb-2016-0017 .

Popević, Spasoje, Šumarac, Zorica, Jovanović, Dragana, Babić, Dragan, Stjepanović, Mihailo, Jovičić, Snežana, Sobić-Saranović, Dragana, Filipović, Snežana, Gvozdenović, Branko, Omcikus, Maja, Milovanović, Andela, Videnović-Ivanov, Jelica, Radović, Ana, Zugić, Vladimir, Vučinić-Mihailović, Violeta, "Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study" in Journal of Medical Biochemistry, 35, no. 4 (2016):390-400,
https://doi.org/10.1515/jomb-2016-0017 . .